The editorial board of Russian Forbes magazine has published a ranking of the largest pharmaceutical companies in 2025. The assessment was based on five criteria: share of local products, sales, revenue change, number of branded drugs in circulation, and number of clinical trial approvals over three years.
The longlist includes the 40 largest Russian manufacturers by sales in 2025, according to AlphaRM. In the preamble to the ranking, the editors noted: "From a business perspective, it's important to consider how a company builds its portfolio, how much it invests in clinical trials used to update its portfolio, and the costs it employs to organize production. All of this impacts a manufacturer's efficiency and sales growth."
Evgenia Shapiro, General Director of PSK Pharma:
"Rus Biopharm's inclusion in Forbes' ranking of the best Russian pharmaceutical companies is a confirmation of the soundness of our strategy and strong performance by industry experts, the medical community, and patients. These high scores reflect competent management, a team of professionals, and significant resources invested in development. We will continue to invest in innovation, the development of modern biopharmaceuticals, and further localization, as the sustainable development of large domestic companies ensures the country's pharmaceutical sovereignty."
